Nutex Health Inc. (NUTX) - What Are Investment Firms Thinking About This Stock?

Key Points

• Analysts maintain a bullish outlook: Nutex Health has a “Moderate Buy” consensus, with four buy ratings and one hold rating. The average 12-month price target is $323.67, above the stock’s reported $209.59 price.
• Institutional interest increased: BlackRock and several other funds opened or expanded positions, while institutional investors collectively own 5.32% of the company. Insider ownership remains substantial at 44.68%, although a director recently sold 203 shares.
• Recent financial results exceeded expectations: Nutex reported quarterly earnings of $9.38 per share versus the $4.95 consensus estimate, despite revenue of $210.75 million coming in slightly below expectations.

Shares of Nutex Health Inc. (NASDAQ:NUTX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $323.67.

A number of analysts have recently commented on NUTX shares. LADENBURG THALM/SH SH began coverage on Nutex Health in a research note on Monday. They issued a "buy" rating and a $336.00 price target for the company. Zacks Research cut Nutex Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 6th. Lake Street Capital reaffirmed a "buy" rating and set a $310.00 price target (up from $235.00) on shares of Nutex Health in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Nutex Health from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, October 6th. Finally, B. Riley Financial reaffirmed a "buy" rating on shares of Nutex Health in a research note on Friday, September 4th.

Insider Buying and Selling

In other Nutex Health news, Director Scott Saunders sold 203 shares of the company's stock in a transaction on Friday, September 18th. The shares were sold at an average price of $214.25, for a total value of $43,492.75. Following the transaction, the director directly owned 400 shares in the company, valued at $85,700. The trade was a 33.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 44.68% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Nutex Health in the 2nd quarter valued at about $69,612,000. Winmill & CO. Inc. acquired a new stake in shares of Nutex Health during the 2nd quarter worth approximately $11,168,000. Empowered Funds LLC acquired a new position in shares of Nutex Health during the 2nd quarter worth $7,720,000. Bank of New York Mellon Corp acquired a new stake in Nutex Health in the second quarter valued at about $3,956,000. Finally, SG Americas Securities LLC grew its position in Nutex Health by 3,232.6% in the first quarter. SG Americas Securities LLC now owns 30,360 shares of the company's stock valued at $2,885,000 after acquiring an additional 29,449 shares during the last quarter. 5.32% of the stock is owned by institutional investors.

Nutex Health Stock Performance

Shares of Nutex Health stock opened at $209.59 on Monday. The firm has a 50 day simple moving average of $201.41 and a 200 day simple moving average of $163.35. Nutex Health has a fifty-two week low of $83.99 and a fifty-two week high of $226.16. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.00 and a quick ratio of 4.96. The firm has a market cap of $1.44 billion, a P/E ratio of 8.23 and a beta of 0.55.

Nutex Health (NASDAQ:NUTX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $9.38 EPS for the quarter, beating the consensus estimate of $4.95 by $4.43. The company had revenue of $210.75 million during the quarter, compared to analysts' expectations of $215.03 million. Nutex Health had a return on equity of 39.74% and a net margin of 21.25%. Sell-side analysts predict that Nutex Health will post 27.58 earnings per share for the current fiscal year.

About Nutex Health

Nutex Health, Inc NASDAQ: NUTX is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.